Gilead Sciences Inc
NASDAQ: GILD
$92.11
-$0.52 (-0.6%)
Closing Price on November 14, 2024
GILD Articles
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
Published:
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is rising on Monday after two analysts made positive calls on the biotech giant. As a reminder, Gilead is now the world’s largest pure-play biotech as...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on is Monday, February 10, 2014. They include Fairway Group, J.P. Morgan, Red Robin and Vodafone.
Published:
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is the biggest biotech company in America, and it is one of the top performers for 2013. Despite having a market cap of well over $100 billion now, this...
Published:
Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
Published:
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board. Investors who...
Published:
Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going forward but can stay intact. They think the fundamental backdrop is...
Published:
The U.S. equity strategy team at UBS has a positive view on stocks heading into 2014, particularly technology, financials and industrials. Here are the names they feel have the absolute greatest...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, December 30, 2013.
Published:
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
Published:
courtesy of Apple Inc.Like most firms that we cover on Wall Street, Piper Jaffray has updated its top names to buy for 2014, and the firm has an extensive market commentary to go along with the...
Published:
ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance...
Published:
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) has been on fire, so much that two insiders decided to stuff their holiday stockings with about $23 million in stock sales. Chairman and CEO John Martin...
Published:
ThinkstockThe DJIA has finally closed above 16,000 for the first time ever. With a light holiday week coming up and with year-end just around the corner, investors have to consider research ideas...
Published:
ThinkstockAny time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from close to nothing...
Published: